trending Market Intelligence /marketintelligence/en/news-insights/trending/rcbh77d64bqp5jpmqme9mw2 content esgSubNav
In This List

MabVax schedules reverse stock split with hopes to regain Nasdaq compliance

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


MabVax schedules reverse stock split with hopes to regain Nasdaq compliance

San Diego-based MabVax Therapeutics Holdings Inc. has scheduled its previously announced 1-to-3 reverse stock split for Feb. 16.

With the stock split, the biotech company hopes to regain compliance with Nasdaq's listing rule that requires a $1.00 minimum closing bid price for at least 10 trading days.

MabVax has until March 5 to regain compliance with the stock market.

The company previously regained compliance with Nasdaq's minimum equity requirement in November 2017.